Market News & Trends
Bladder Cancer Market to Witness Moderate Growth by 2017
The bladder cancer therapeutics market in the six major countries (6MM) - the US, France, Germany, Italy, Spain, and UK - is forecast to climb…
Biocon Collaborates With Advaxis
Biocon Ltd. and Advaxis, Inc. recently announced they have entered into an exclusive licensing agreement for co-development and commercialization of ADXS-HPV, a novel cancer immunotherapy…
Alitair Announces Issuance of Third Patent for its Drug Delivery Platform
Alitair Pharmaceuticals, Inc. recently announced the issuance of US Patent No. 8,617,602 from theUSPTO for its ion exchange resin drug delivery technology, REA. "Our…
Bristol-Myers Seeks Innovative Drugs
Bristol-Myers Squibb Co. will continue to seek out innovative drugs to buy, particularly for cancer, shrugging off two previous deals totaling $7.8 billion in the…
Valeant, Actavis, Mylan Pursue Pfizer's Generics Unit
Drugmakers Valeant Pharmaceuticals International Inc., Actavis Plc, and Mylan Inc. have all expressed interest in buying Pfizer Inc's branded generics business, but no active discussions…
Moderna Launches Spin-Off for mRNA-Based Cancer Drugs
With a $110-million financing round and big-time deals with AstraZeneca and Alexion Pharmaceuticals in the bag, biotech company Moderna Therapeutics’ next big move is to…
Monoclonal Antibodies Market for Gastric & Esophageal Cancers to Double by 2019
Due to favorable market conditions in terms of US pricing structures and the anticipated approval of a number of late-stage pipeline drugs, the market value…
Isis Pharmaceuticals, Inc. to Receive $7.5 Million From Alnylam
Isis Pharmaceuticals, Inc. recently announced it will receive $7.5 million from Alnylam Pharmaceuticals, Inc. from the recently announced alliance between Genzyme and Alnylam. In addition,…
NantBioScience Announces Strategic Collaboration With Celgene
NantBioScience recently announced a strategic collaboration with Celgene to advance bold research programs to benefit cancer patients in need of new therapeutic solutions. As part…
AAIPharma Announces Completion of Parenteral Manufacturing Facility Expansion
AAIPharma Services Corp recently announced it has completed a multi-million dollar expansion of its cGMP parenteral manufacturing facility in Charleston, SC. The expansion consisted of…
CytomX Therapeutics & ImmunoGen Announce Strategic Collaboration
CytomX Therapeutics and ImmunoGen, Inc. recently announced a multi-year, strategic collaboration to develop Probody-drug conjugate (PDC) therapies for the treatment of cancer. Probodies are a…
Aptalis to be Acquired by Forest Laboratories for $2.9 Billion
Aptalis recently announced that it has signed a definitive agreement to be acquired by Forest Laboratories, Inc. Forest has agreed to acquire Aptalis from TPG,…
Revamped Therapies Preventing Visual Impairment Primed to Revolutionize US Retinal Therapeutics Market
The need for effective and patient-friendly treatment of retinal diseases to avoid visual impairment is driving the retinal therapeutics market in the US. Vascular endothelial…
Marina Biotech Strengthens IP Estate for SMARTICLES Nucleic Acid Delivery Technology
Marina Biotech, Inc. recently announced the grant and issuance of patents relating to the company's proprietary nucleic-acid delivery technology, SMARTICLES. The US Patent and Trademark…
Santaris A/S Announces Worldwide Discovery Alliance for RNA-Targeted Medicines With Roche
Santaris Pharma A/S recently announced it has signed a worldwide strategic alliance with Roche to discover and develop novel RNA targeted medicines using Santaris Pharma's…
New Report on Global Markets for Advanced Drug Delivery Systems
According to a new technical market research report, Global Markets and Technologies for Advanced Drug Delivery Systems, from BCC Research (http://www.bccresearch.com), the global market for…
DNAnexus, Inc. Secures $15 Million in Financing, Led by Google Ventures
DNAnexus recently announced it has closed a $15-million Series C funding led by Claremont Creek Ventures, Google Ventures, TPG Biotech, and First Round Capital. The…
Scioderm Initiates Phase IIB Study
Scioderm, Inc. recently announced the initiation of a Phase IIB study designed to evaluate the efficacy and safety of SD-101, a novel topical therapy, for…
FDA Endorses, Pushes for Abuse-Resistant Opioid Formulations: Transition to Disrupt Pain Market
The opioid market is dominated by non-tamper-resistant formulations (TRFs), but the FDA’s promotion of TRF therapies could well result in the departure of non-TRF therapies…
Merck Plans Radical Overhaul of R&D Unit
Merck & Co. Inc. is working on a plan to radically reshape its once-storied R&D unit that would create international innovation hubs tapping into drug…
